Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples

Metini Janyasupab; Ying-Hui Lee; Yuan Zhang; Chen W Liu; Jieyi Cai; Adriana Popa; Anna C Samia; Kuan W Wang; Jiaqiang Xu; Chi-Chang Hu; Michael K Wendt; Barbara J Schiemann; Cheryl L Thompson; Yun Yen; William P Schiemann; Chung C Liu

doi:10.2174/2210309005666150804195033

Journal article

Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples

Metini Janyasupab, Ying-Hui Lee, Yuan Zhang, Chen W Liu, Jieyi Cai, Adriana Popa, Anna C Samia, Kuan W Wang, Jiaqiang Xu, Chi-Chang Hu, …

Recent patents on biomarkers, Vol.5(2), pp.93-100

01/01/2015

DOI: 10.2174/2210309005666150804195033

PMCID: PMC5493150

PMID: 28670509

View Online

Abstract

Metastasis accounts for 90% of the mortality associated with breast cancer. Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix. LOXs are linked to the development and metastatic progression of breast cancers. Accordingly, aberrant expression of LOX-like 2 (LOXL2) is observed in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival. Therefore, LOXL2 expression may serve as a biomarker for breast cancer. Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine. We exploited this chemistry to generate a revolutionary gold-based electrochemical biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples. Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients. Limited numbers of urine specimens from breast cancer patients were also tested. Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer. This work is described in WO 052962 A1 (2014).

metastasis of breast cancers

thin gold film biosensor

Biomarker

lysyl oxidase-like 2 (LOXL2)

Details

Title: Subtitle: Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples
Creators: Metini Janyasupab - Biomedical Engineering, King Monkut's Institute of Technology, Bangkok, Thailand
Ying-Hui Lee - Material (Belgium)
Yuan Zhang - College of Science, Shanghai University, Shanghai, 200444, China
Chen W Liu - Green Energy & Environmental Research Laboratory, Industrial Technology Research, Institute (ITRI), Hsing Chu, Taiwan
Jieyi Cai - Brown University
Adriana Popa - Case Western Reserve University
Anna C Samia - Case Western Reserve University
Kuan W Wang - Institute of Materials & Engineering, National Central University, Jhongli, 320, Taiwan
Jiaqiang Xu - College of Science, Shanghai University, Shanghai, 200444, China
Chi-Chang Hu - National Tsing Hua University
Michael K Wendt - Case Western Reserve University
Barbara J Schiemann - Case Western Reserve University
Cheryl L Thompson - Case Western Reserve University
Yun Yen - Taipei Medical University
William P Schiemann - Case Western Reserve University
Chung C Liu - Biomedical Engineering, King Monkut's Institute of Technology, Bangkok, Thailand
Resource Type: Journal article
Publication Details: Recent patents on biomarkers, Vol.5(2), pp.93-100
DOI: 10.2174/2210309005666150804195033
PMID: 28670509
PMCID: PMC5493150
NLM abbreviation: Recent Pat Biomark
ISSN: 2210-3090
eISSN: 2210-3104
Grant note: P30 CA043703 / NCI NIH HHS R01 CA177069 / NCI NIH HHS R01 CA129359 / NCI NIH HHS R00 CA166140 / NCI NIH HHS K99 CA166140 / NCI NIH HHS
Language: English
Date published: 01/01/2015
Academic Unit: Internal Medicine
Record Identifier: 9984460328402771

Metrics

5 Record Views